News
-
-
-
-
-
-
PRESS RELEASE
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Mainz Biomed provides Q1 2025 corporate update on FDA premarket approval path, including study enrollment, partnership with Liquid Biosciences and labor team w ag, and product launches. CEO Guido Baechler comments on progress -
-
-
-